RECENT INSIDER SALES WERE FOR TAX PURPOSES PEOPLE!!!!! Additionally, Zogenix supposedly has best abuse deterrent (strong opinion) than any other company from what I have read. That is basaed on the Altus formulation, not the 1st on in progress. I am 95% certain they will formally release the information on the 18th at the healthcare conference they are scheduled to present. Additionally, Zogenix (NASDAQ:ZGNX) Director Cam L. Garner bought 30,000 shares of the stock in a transaction dated Friday, June 13th. The shares were purchased at an average cost of $1.66 per share, with a total value of $49,800.00. Following the completion of the purchase, the director now directly owns 326,750 shares in the company, valued at approximately $542,405. The transaction was disclosed in a document filed with the SEC, which is available at this link.
1. The company is 89.85% institutionally owned - an increase from 87% in March.
2. Zohydro has 3-yr drug exclusivity for any single Hydrocodone ER drug, AD or not.
3. There are two AD formulas in progress. One will be released soon Q4 14' or Q1 '15 and does NOT have to go through clinical trials, and the other version (by Altus) does not have to go through FDA Phase 2 OR 3 trials if they can prove bioequivalence, which is +\-20%. The AD formulations will extend their patents.
5. Zogenix announced publicly on its last conference call other drug companies were behind the slander and anti-zohydro campaign.
6. The company received buy-out offers, but rejected them, hence why the negative campaign started in the first place. The CEO stated this in the last conference call. Because this was stated publicly I am curious if there is any type of investigation.
7. Zohydro is less potent than most ER opioids on the market, and most of them don't have AD properties.
8. The short interest has decreased over the last two reporting periods.
9. Purdue's NDA will backfire. It will either be denied by the FDA outright, or if accepted, Zogenix will sue for patent infringement and win.
10. Zogenix has more than enough money to last them through the end of the year.
11. The company is debt-free.
12. Their needless injection system has the potential to replace the needle.
13. Zogenix has more than just Zohydro in their pipeline. Relday is scheduled for 2016 and will be ENORMOUS. Relday is better than Johnson & Johnson’s Risperdal that has over $1 billion annual sales
14. The recent insider sells were for tax purposes. The company published an 8-k to clarify any misunderstandings. The insiders still hold a large amount of shares and have options to buy hundreds of thousands more at a fixed low price. The options expire years from now. Hence, there is no rush for them to buy shares right now.
The info is from someone else's post on Yahoo and I revised it a tad.
AI
